

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2005. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/777,043		
		Filing Date	February 13, 2004		
		First Named Inventor	Eliezer Rapaport		
		Art Unit	1623		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	21095-00008-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JDA	AA	US-5,900,407-A1	05-04-1999	YERXA et al.	
JDA	AB	US-5,017,564	05-1991	Makino et al	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number-Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
JDA	CA	VOET et al., Fundamentals of Biochemistry, John Wiley & Sons, Inc., 1999, p. 44.			
JDA	CB	Remington's Pharmaceutical Sciences, Fifteenth Edition, 1975, pp. 1587 and 1814-1815.			
JDA	CC	Paul J. ARCIERO et al., AGE and NE and FFA Kinetics After Caffeine Ingestion, pp. E1192-E1198, Effects of Caffeine Ingestion on NE Kinetics, Fat Oxidation, and Energy Expenditure in Younger and Older Men.			
JDA	CD	G. BURNSTOCK, Part 1. Biological Effects of Extracellular ATP and Nucleotides, pp. 1-17, Purinergic Mechanisms.			
JDA	CE	Council on Scientific Affairs, Council Report, JAMA, 1988, vol. 260, No. 17, pp. 2547-2551, Treatment of Obesity in Adults.			
JDA	CF	HOPPE et al., 16. Desensitization of A1 Adenosine Receptors, pp. 133-138.			
JDA	CG	Kenneth A. JACOBSON et al., Purinergic Approaches in Experimental Therapeutics, 1997, pp. 102-129, Development of Selective Purinoceptor Agonists and Antagonists.			
JDA	CH	Kollas-BAKER et al., 26. Myocardial Adenosine Receptors, pp. 221-228.			
JDA	CI	Kathryn La NOUE et al., The FASEB Journal, 1994, vol. 8, pp. 72-80, Abnormal A1 Adenosine Receptor Function in Genetic Obesity.			
JDA	CJ	H. Thomas LEE et al., The American Physiological Society, 1993, pp. H1918-H1927, Cardiac Desensitization to Adenosine Analogues After Prolonged R-PIA Infusion In Vivo.			
JDA	CK	Joel LINDEN, The FASEB Journal, 1991, vol. 5 pp. 2668-2676, Structure and Function A1 Adenosine Receptors.			
JDA	CL	Joel LINDEN, Purinergic Approaches in Experimental Therapeutics, 1997, pp. 84-97, Allosteric Enhancement of Adenosine Receptors.			
JDA	CM	Khalid A. MOHAMEDALI et al., The Journal of Biological Chemistry, 1993, vol. 268., No. 31, pp. 23728-23733, The Highest Levels of Purine Catabolic Enzymes in Mice are Present in the Proximal Small Intestine.			
JDA	CN	Eliezer RAPAPORT, Department of Microbiology, pp. 142-149, Mechanisms of Anticancer Activities of Adenine Nucleotides in Tumor-Bearing Hosts.			

Examiner Signature		Date Considered	3/22/06
--------------------	---	-----------------	---------

PTO/SB/08a/b (09-03)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/SB/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/777,043		
		Filing Date	February 13, 2004		
		First Named Inventor	Eliezer Rapaport		
		Art Unit	1623		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	21095-00008-US1

JDA	CO	Eliezer RAPAPORT et al., Proc. Natl. Acad. Sci. USA, 1976, vol. 73, No. 9, pp. 3122-3125, Incorporation of Adenosine Into ATP: Formation of Compartmentalized ATP.	
JDA	CP	Eliezer RAPAPORT et al., Biochemical Pharmacology, 1989, vol. 38 No. 23 pp. 4261-4266, Generation of Extracellular ATP in Blood and its Mediated Inhibition of Host Weight Loss in Tumor-Bearing Mice.	
JDA	CQ	Eliezer Rapaport et al., Proc. Natl. Acad. Sci., 1989, vol. 86, pp. 1662-1666, Anticancer Activities of Adenine Nucleotides In Mice Are Mediated Through Expansion of Erythrocyte ATP Pools.	
JDA	CR	John SHRYOCK et al., The American Physiological Society, 1989, pp. H321-H327, Downregulation And Desensitization of A1-Adenosine Receptors in Embryonic Chicken Heart.	
JDA	CS	Linda L. SLAKEY et al., Part V. Metabolism and Utilization of Extracellular ATP by Ectoenzymes, pp. 366-379, A Comparison of Ectonucleotidase Activities On Vascular Endothelial and Smooth Muscle Cells.	
JDA	CT	PH. Van Der GRAFF et al., The Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 290, No.2, pp.702-709, Mechanism-Based Pharmacokinetic-Pharmacodynamic Modelling of Antilipolytic Effects of Adenosine A1 Receptor Agonists In Rats: Prediction of Tissue-Dependent Efficacy in Vivo.	
JDA	CU	E.A. Van SCHAICK et al., The Journal Of Pharmacology and Experimental Therapeutics, 1998, vol. 287, No. 1, pp. 21-30, Metabolic And Cardiovascular Effects of The Adenosine A1 Receptor Agonist N6-(p-Sulfophenyl) Adenosine In Diabetic Zucker Rats: Influence of the Disease on the Selectivity of Action.	
JDA	CV	Michael WILLIAMS et al., Purinergic Approaches In Experimental Therapeutics, 1997, pp. 3-28, Purinergic Neurotransmission and Neuromodulation a Historical Perspective.	
JDA	CW	Baiyand XU et al., The American Physiological Society, 1998, pp. E271-E279, A1 Adenosine Receptor Antagonism Improves Glucose Tolerance In Zucker Rats.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/22/06
-----------------------	---	--------------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	21095-00008-US1
-------	---	----	---	------------------------	-----------------

**Complete if Known**

Application Number	10/777,043-Conf. #3919
Filing Date	February 13, 2004
First Named Inventor	Eliezer Rapaport
Art Unit	1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	21095-00008-US1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
JDA	AA	US-5,547,942-A	08-20-1996	Rapaport, Eliezer	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
JDA	BA	EP-0 348 688-A1	01-03-1990	Senju Pharmaceutical Co., Ltd.		
JDA	BB	EP-0 344 795-A1	12-06-1989	Senju Pharmaceutical Co., Ltd.		
JDA	BC	EP-0 352 477-A2	01-31-1990	Rapaport, Eliezer		
JDA	BD	WO-93/21783-A1	11-11-1993	The Penn State Research Foundation		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>7</sup>
JDA	CA	"Attenuated adenosine-sensitivity and decreased adenosine-receptor number in adipocyte plasma membranes in human obesity" by Kaartinen et al., <i>Biochem. J.</i> (1991) 279, pages 17-22.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/22/06
-----------------------	---	--------------------	---------